タナカ リョウジロウ   Ryojiro Tanaka
  田中 亮二郎
   所属   川崎医科大学  医学部 臨床医学 小児科学
   職種   特任教授
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Prediction of AESD and neurological sequelae in febrile status epilepticus.
掲載誌名 正式名:Brain & development
略  称:Brain Dev
ISSNコード:18727131/03877604
掲載区分国外
巻・号・頁 43(5),pp.616-625
著者・共著者 Masahiro Nishiyama, Yusuke Ishida, Hiroshi Yamaguchi, Shoichi Tokumoto, Kazumi Tomioka, Hiroto Hongo, Daisaku Toyoshima, Azusa Maruyama, Hiroshi Kurosawa, Ryojiro Tanaka, Kandai Nozu, Kazumoto Iijima, Hiroaki Nagase
発行年月 2021/05
概要 OBJECTIVE:The clinical prediction rule (CPR) for acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) was developed with an area under the receiver operating characteristic curve (AUC) of 0.95 - 0.96. Our objective was to verify the AESD CPR in a new cohort and compare the utilities of three CPRs of acute encephalopathy: the Tada, Yokochi, and Nagase criteria.METHODS:We reviewed the clinical data and medical charts of 580 consecutive patients (aged < 18 years) with febrile convulsive status epilepticus lasting for ≥ 30 min in 2002 - 2017 and measured the performance of the CPRs in predicting AESD and sequelae.RESULTS:The CPRs predicted AESD with an AUC of 0.84 - 0.88. The Tada criteria predicted AESD with a positive predictive value (PPV) of 0.25 and a negative predictive value (NPV) of 0.99. The Yokochi criteria predicted AESD with a PPV and NPV of 0.20 and 0.95, respectively, after 12 h. The Nagase criteria predicted AESD with a PPV and NPV of 0.14 and 1.00, respectively, after 6 h. The PPVs of the Tada, Yokochi, and Nagase criteria for sequelae were 0.28, 0.28, and 0.17, respectively; the corresponding NPVs were 0.97, 0.95, and 0.98, respectively.CONCLUSIONS:The effectiveness of the AESD CPR in a new cohort was lower than that in the derivation study. CPRs are not sufficient as diagnostic tests, but they are useful as screening tests. The Nagase criteria are the most effective for screening among the three CPRs due to their high NPV and swiftness.
DOI 10.1016/j.braindev.2021.01.004
PMID 33563484